Collectively, these findings provide the first evidence that IGF2BP1 inhibition enhances immune checkpoint therapy by disrupting IGF2BP1-driven uncoupling of IRF1-dependent MHC-I/PD-L1 synthesis in tumor cells (Fig. 6m). The gene discussed is IRF1; the disease is neoplasm.